Launch teams

Case study 1
“Our product is complex. There are many rules about when and how it may be used. Its complexity may put off prescribers and patients if we are not careful. We need to engage with the rising stars who are comfortable with this type of technology. We need their support to train their peers and patients.”

Case study 2
“Our Medical Division has set an ambitious goal to run 12International and Continental advisory boards in the next 18 months. The issue we’re having is deciding who to invite to each event, there are many competing opinions. We just need a more evidence-based approach.”

Case study 3
“We launched our product 18 months ago. Our performance does not match our expectations. We would like to dive deeper into a single market, to find the people who are interested in our therapeutic condition at a local level. We are trying to find new people to talk to.”

‍

“Launch excellence in biopharmaceuticals is a discipline requiring discipline!” said one of our clients, “We need to overcome our biases, and work hard to engage with people we don’t usually talk to, because they have influence in places with their peers that we cannot match.”

Over the past 30 years we have moved from launch teams requesting “no more than” 10-15 Key Opinion Leaders (KOLs) in a specific country to help with their launch, to teams today asking for a “full landscape view of established KOLs, Rising Stars (tomorrow’s leaders), Digital Opinion Leaders (DOLs) and Patient Groups”.

The complexity of modern medicine is such that clinicians, patients, and payers need significant education about the science, technology, economics, and risks associated with each new therapeutic. That takes time, and it needs collaboration to get right, and be accepted.

That’s why we have developed an online platform called Thecosystems – it is a curated view of a single therapeutic ecosystem. It contains the movers and shakers: those holding positions of authority and influence in a therapeutic area, and those whose voices others trust when deciding to adopt an innovation for the first time.  

‍Learn more about how we can help throughout the R&D Lifecycle →